9HVW

Respiratory Syncytial Virus Fusion protein in the postfusion conformation in complex with monoclonal antibody 131-2a Fab

This is a non-PDB format compatible entry.

Summary for 9HVW

• Entry DOI: 10.2210/pdb9hvw/pdb
• EMDB information: 52444
• Descriptor: Fusion glycoprotein F0, Fusion glycoprotein F1,Probable N-acetylmuramidase, 131-2a heavy chain, ... (4 entities in total)
• Functional Keywords: antigenic site i, viral protein
• Biological source: human respiratory syncytial virus; More
• Total number of polymer chains: 8
• Total formula weight: 219086.15

Authors

Snijder, J. (deposition date: 2025-01-02, release date: 2025-02-26, Last modification date: 2025-08-20)

Primary citation

Peng, W.,Siborova, M.,Wu, X.,Du, W.,Schulte, D.,Pronker, M.F.,de Haan, C.A.M.,Snijder, J.
Structural Basis for Postfusion-Specific Binding to the Respiratory Syncytial Virus F Protein by the Canonical Antigenic Site I Antibody 131-2a.
Acs Infect Dis., 11:2357-2366, 2025

PubMed Abstract: The respiratory syncytial virus (RSV) fusion (F) protein is a major target of antiviral antibodies following natural infection or vaccination and is responsible for mediating fusion between the viral envelope and the host membrane. The fusion process is driven by a large-scale conformational change in F, switching irreversibly from the metastable prefusion state to the stable postfusion conformation. Previous research has identified six distinct antigenic sites in RSV-F, termed sites Ø, I, II, III, IV, and V. Of these, only antigenic site I is fully specific to the postfusion conformation of F. A monoclonal antibody 131-2a that specifically targets postfusion F has been widely used as a research tool to probe for postfusion F and to define antigenic site I in serological studies, yet its sequence and precise epitope have remained unknown. Here, we use mass spectrometry-based sequencing of 131-2a to reverse engineer a recombinant product and study the epitope to define antigenic site I with molecular detail, revealing the structural basis for the antibody's specificity toward postfusion RSV-F.

PubMed: 40693554
DOI: 10.1021/acsinfecdis.5c00368

Experimental method

ELECTRON MICROSCOPY (3.1 Å)